Human Genome Epidemiology Literature Finder
Records 1 - 5 (of 5 Records) |
Query Trace: Colorectal Neoplasms and TYMP[original query] |
---|
Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PloS one 2013 8 (10): e78053. Jennings Barbara A, Loke Yoon K, Skinner Jane, Keane Melanie, Chu Gavin S, Turner Richard, Epurescu Daniel, Barrett Ann, Willis Gav |
Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacological research 2017 Mar 120 133-137. Pellicer Marta, García-González Xandra, García María I, Robles Luis, Grávalos Cristina, García-Alfonso Pilar, Pachón Vanessa, Longo Federico, Martínez Virginia, Blanco Carolina, Iglesias Irene, Sanjurjo María, López-Fernández Luis |
[The influence of Thymidine Phosphorylase genetic variation on clinical outcomes and safety of colorectal cancer patients received adjuvant chemotherapy after R0 resection]. Zhonghua yi xue za zhi 2018 9 98 (32): 2569-2573. Du Y B, Zhang T F, Cui K, Jin S L, Xi Y, Ma |
Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer. The pharmacogenomics journal 2019 Dec . Reynolds Ian S, O'Connell Emer, Fichtner Michael, McNamara Deborah A, Kay Elaine W, Prehn Jochen H M, Furney Simon J, Burke John |
Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy. Pharmacogenomics and personalized medicine 2023 4 16 277-289. Jia Xiongjie, Zhang Tao, Sun Junjie, Lin Hengxue, Bai Tianliang, Qiao Yating, Li Yaxin, Li Gang, Li Guicun, Peng Xinyu, Zhang Aim |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source: